LifeMD, Inc. announced a new strategic partnership designed to revolutionize weight management patient care by providing LifeMD?s GLP-1 weight-loss patients with Withings advanced in-home health monitoring devices, including the Body Pro 2 scale and the BPM Connect Pro blood pressure monitor. With these devices, LifeMD is setting a new standard in virtual care by providing clinicians with near real-time and actionable patient data that can drive compliance, enhance clinical decision-making, encourage preventive healthcare and, most importantly, improve long-term outcomes. LifeMD?s GLP-1 weight-loss program is uniquely positioned to support patients on their weight-loss journey and make healthy living accessible by providing online consultations with licensed clinicians, prescriptions for weight management medications and orders for full-service laboratory testing.

By leveraging the detailed health data from Withings? in-home health monitoring devices, LifeMD aims to gain deeper insight into the effectiveness of GLP-1 treatments and their impact on overall health. This partnership also lays the groundwork for pioneering real-world evidence studies.

Body Pro 2 is the first cellular body composition scale that measures weight and provides a comprehensive analysis of body composition including body fat, muscle mass, water percentage and bone mass. With Body Pro 2, LifeMD benefits from a device that puts patient care at the forefront with features such as Personalized Health Nudges, allowing care teams to send personalized messages to patients through the scale?s screen, and ProgramMemberID, Withings exclusive patient recognition feature to assure the measurement came from the patient rather than from another user. BPM Connect Pro offers medically accurate blood pressure monitoring, enabling healthcare providers to track changes in blood pressure alongside weight-loss progress.

As GLP-1 medications can lower the risk of cardiovascular events, BPM Connect Pro offers LifeMD-affiliated providers a comprehensive view of their patients? progress and the knowledge to adjust their medications, if necessary. Both devices utilize cellular connectivity, ensuring that LifeMD receives HIPAA-compliant, accurate and reliable measurements continuously, displayed in near real-time via the LifeMD patient portal for use by the patient and clinical team.

Thanks to cellular connectivity, the devices work right out of the box and require no installation. This partnership not only is a significant advancement in GLP-1 weight-loss treatment, but it also exemplifies the potential of digital health technology to transform patient care and outcomes in the virtual care landscape.